STAT+: Gilead to buy Arcellx in nearly $8B deal

Chronological Source Flow
Back

AI Fusion Summary

Gilead Sciences is acquiring biotech firm Arcellx for up to $7.8 billion to bolster its cancer drug pipeline. The deal, valuing Arcellx at $115 per share, expands their existing partnership on a CAR-T therapy for multiple myeloma.
#Gilead Sciences #Arcellx #acquisition #biotech #CAR-T therapy #multiple myeloma #cancer drugs #merger
23/02 13:03 statnews.com
2 Πηγές

STAT+: Gilead to buy Arcellx in nearly $8B deal

23/02 17:34 mercurynews.com

Gilead to buy US biotech Arcellx for up to $7.8 billion

Comments
Loading...
0